Sign up to save your podcasts
Or
Share IMPRESS Trial: Navigating the Switch to Chemo From a TKI
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
IMPRESS Trial: Navigating the Switch to Chemo From a TKI
Dr Mark Kris discusses the details of the IMPRESS trial, which assessed the effect of discontinuing gefitinib in patients with EGFR-mutant lung cancer who have developed resistance to the drug.
View all episodes
By MedscapeDr Mark Kris discusses the details of the IMPRESS trial, which assessed the effect of discontinuing gefitinib in patients with EGFR-mutant lung cancer who have developed resistance to the drug.